A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
- Conditions
- Solid Tumors, KRAS Mutation
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT04973163
- Locations
- 🇬🇧
The Christie, Manchester, United Kingdom
🇧🇪Brussels - HOSP Jules Bordet, Anderlecht/Brussels-Capital, Belgium
🇧🇪Edegem - UNIV UZ Antwerpen, Edegem/Antwerpen, Belgium
A Study in Healthy Men to Test How BI 474121 is Tolerated
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT04964453
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT04958252
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 160
- Registration Number
- NCT04958239
- Locations
- 🇲🇽
Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico
🇺🇸The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT04938453
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16746
- Registration Number
- NCT04937816
- Locations
- 🇩🇪
Boehringer Ingelheim, Ingelheim am Rhein, Germany
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT04937829
- Locations
- 🇺🇸
Research Centers of America, Oakland Park, Florida, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸Optimus U Corporation, Miami, Florida, United States
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 460558
- Registration Number
- NCT04927858
- Locations
- 🇸🇪
Boehringer Ingelheim AB, Stockholm, Sweden
A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body
- Conditions
- Healthy
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT04926246
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Device: Sp(t)iolto® Respimat®
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1371146
- Registration Number
- NCT04926233
- Locations
- 🇺🇸
AETION inc, New York, New York, United States